Windlas Biotech's New State-of-the-art Injectable Facility Receives GMP Certification
Windlas Biotech Limited, a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) in India, has received Good Manufacturing Practices (GMP) certification for its new State-of-the-Art Injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand. The certification validates Windlas Biotech's adherence to stringent manufacturing protocols and strengthens its ability to meet the growing demand for high-quality injectable pharmaceutical products. The state-of-the-art facility, equipped with automated systems, robust quality control mechanisms, and eco-friendly processes, enables Windlas Biotech to expand its product portfolio offerings in the CDMO space and cater to a wider spectrum of therapeutic areas.
Key Highlights
- Windlas Biotech's new State-of-the-Art Injectable facility receives GMP Certification from the Food Safety & Drugs Administration Authority of Uttarakhand.
- The certification marks a new chapter in Windlas Biotech's growth trajectory and strengthens its reputation as a trusted name in the pharmaceutical manufacturing sector.
- The GMP certification for the injectable facility underscores Windlas Biotech's commitment to quality, innovation, and compliance with the highest regulatory standards.
- The state-of-the-art facility is equipped with advanced infrastructure and automated systems to ensure efficient and safe production of sterile injectable formulations.
- The new GMP-certified injectable facility enables Windlas Biotech to expand its product portfolio offerings in the CDMO space and cater to a wider spectrum of therapeutic areas.